AbbVie tops estimates in the second quarter
AbbVie released its second-quarter results this morning, posting an Adjusted EPS of $0.82 on $4.926 billion in revenue. By contrast, Wall Street was expecting an Adjusted EPS of $0.76 on $4.7 billion in revenue.
This earnings beat was driven primarily by a nice bump in Humira sales, which increased by a noteworthy 26.2% to $3.3 billion on a global basis, compared to the same period a year ago. The company also saw decent sales growth for Synthroid, Sevoflurane and Duodopa in the quarter.
AbbVie didn't, however, provide much in the way of an updated guidance that reflects the acquisition of Shire. My take is that the impact of this acquisition is still being assessed given that the deal was only announced last week.
Nevertheless, this merger is a game-changer that investors should closely following moving forward. The tax consequences alone should make an immediate impact on AbbVie's bottom line. Moreover, Shire recently posted yet another strong quarter in terms of growing product sales, which will likely translate to better top-line growth for AbbVie in the near future.
More bribery allegations for GlaxoSmithKline
Shares of GlaxoSmithKline are falling today after news broke that the company is facing additional bribery allegations--this time in Syria. Last week, Glaxo reportedly informed its compliance department that a whistleblower emailed the company alleging that employees in Syria were offering bribes to increase sales for its consumer health products.
What's key to understand is this is another company where Glaxo employees have been accused of bribery in an attempt to boost sales. The Department of Justice in the U.S. and the U.K. Serious Fraud Office reportedly have opened investigations into the company, with a keen interest in understanding whether a "pattern of corruption" exists. If so, we could see Glaxo get hit with yet another record fine.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.